InVivo Therapeutics
-
Financial
InVivo Therapeutics Announces Closing of $3.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
April 17, 2020 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced the closing of its previously announced registered direct offering…
Read More » -
Financial
InVivo Therapeutics Announces Closing of $7.0 Million Public Offering
March 11, 2020 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering…
Read More » -
Biologics
InVivo Therapeutics Announces Appointment of Robert Rosenthal to Board of Directors
November 12, 2019 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Robert J. Rosenthal, Ph.D., to the…
Read More » -
Financial
InVivo Therapeutics Reports 2018 Year-end Financial Results and Provides Business Update
April 01, 2019 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2018.…
Read More » -
Financial
InVivo Therapeutics Announces Richard Christopher as CFO and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 14, 2019 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus…
Read More » -
Financial
InVivo Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update
November 08, 2018 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today provided a business update and reported financial results for the…
Read More » -
Biologics
InVivo Therapeutics Announces Joint Research Collaboration with Q Therapeutics, Inc.
October 02, 2018 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a…
Read More » -
Financial
InVivo Therapeutics Reports 2018 Second Quarter Financial Results
August 07, 2018 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today provided a business update and reported financial results for the…
Read More » -
Financial
InVivo Therapeutics Announces Pricing of $13.2 Million Underwritten Public Offering
June 21, 2018 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of an underwritten public offering of 388,403…
Read More » -
Financial
InVivo Therapeutics Reports 2018 First Quarter Financial Results
May 07, 2018 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today provided a business and clinical update and reported financial results…
Read More » -
Financial
InVivo Therapeutics Provides Business Update
April 09, 2018 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq:NVIV) today provided a general business update. The company is announcing a…
Read More » -
Hospitals
InVivo Therapeutics Receives FDA Approval for Pivotal, Randomized, Controlled Trial of the Neuro-Spinal Scaffold™ in Patients with Acute Spinal Cord Injury
March 08, 2018 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company has received supplemental Investigational Device Exemption…
Read More » -
Biologics
InVivo Therapeutics Announces Appointment of Richard Toselli, M.D., as President and Chief Executive Officer
February 05, 2018 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that Richard Toselli, M.D., has been appointed President and…
Read More » -
Financial
InVivo Therapeutics Announces Purchase Agreement for up to $15 Million with Lincoln Park Capital
January 26, 2018 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that it has entered into a common stock…
Read More » -
Biologics
InVivo Therapeutics Announces Executive Management and Board Changes
December 18, 2017 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that Richard Toselli, M.D., has been appointed Acting Chief…
Read More »